Works matching DE "DOLUTEGRAVIR"

Results: 216
    1
    2
    3
    4
    5

    Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub‐study of the ODYSSEY randomized controlled trial.

    Published in:
    Journal of the International AIDS Society, 2023, v. 26, n. 9, p. 1, doi. 10.1002/jia2.26174
    By:
    • Barlow‐Mosha, Linda Namutebi;
    • Ahimbisibwe, Grace Miriam;
    • Chappell, Elizabeth;
    • Amuge, Pauline Mary;
    • Nanduudu, Annet;
    • Kaudha, Elizabeth;
    • Amukele, Timothy;
    • Balamusani, David;
    • Kafufu, Bosco;
    • Nimwesiga, Audrey;
    • Kataike, Hajira;
    • Namwanje, Rosemary;
    • Kasangaki, Gladys;
    • Mulindwa, Alice;
    • Muzorah, Gerald Agaba;
    • Bbuye, Dickson;
    • Musiime, Victor;
    • Mujyambere, Emmanuel;
    • Ssenyonga, Mark;
    • Mulima, Disan
    Publication type:
    Article
    6

    Diagnostic accuracy of a point‐of‐care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz‐based antiretroviral therapy.

    Published in:
    Journal of the International AIDS Society, 2023, v. 26, n. 9, p. 1, doi. 10.1002/jia2.26172
    By:
    • Dorward, Jienchi;
    • Lessells, Richard;
    • Govender, Katya;
    • Moodley, Pravi;
    • Samsunder, Natasha;
    • Sookrajh, Yukteshwar;
    • Turner, Phil;
    • Butler, Christopher C.;
    • Hayward, Gail;
    • Gandhi, Monica;
    • Drain, Paul K.;
    • Garrett, Nigel
    Publication type:
    Article
    7
    8

    Weight gain during the dolutegravir transition in the African Cohort Study.

    Published in:
    Journal of the International AIDS Society, 2022, v. 25, n. 4, p. 1, doi. 10.1002/jia2.25899
    By:
    • Esber, Allahna L.;
    • Chang, David;
    • Iroezindu, Michael;
    • Bahemana, Emmanuel;
    • Kibuuka, Hannah;
    • Owuoth, John;
    • Singoei, Valentine;
    • Maswai, Jonah;
    • Dear, Nicole F.;
    • Crowell, Trevor A.;
    • Polyak, Christina S.;
    • Ake, Julie A.
    Publication type:
    Article
    9
    10

    Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single‐tablet regimen in a multicentre cohort in Spain.

    Published in:
    Journal of the International AIDS Society, 2021, v. 24, n. 7, p. 1, doi. 10.1002/jia2.25758
    By:
    • Suárez‐García, Inés;
    • Alejos, Belén;
    • Ruiz‐Algueró, Marta;
    • García Yubero, Cristina;
    • Moreno, Cristina;
    • Bernal, Enrique;
    • Pérez‐Is, Laura;
    • Zubero, Zuriñe;
    • Zárraga Fernández, Miguel Alberto;
    • Samperiz Abad, Gloria;
    • Jarrín, Inma
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22

    Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV Trial.

    Published in:
    Open Forum Infectious Diseases, 2024, v. 11, n. 11, p. 1, doi. 10.1093/ofid/ofae618
    By:
    • Marinosci, Annalisa;
    • Sculier, Delphine;
    • Wandeler, Gilles;
    • Yerly, Sabine;
    • Stoeckle, Marcel;
    • Bernasconi, Enos;
    • Braun, Dominique L;
    • Vernazza, Pietro;
    • Cavassini, Matthias;
    • Decosterd, Laurent;
    • Günthard, Huldrych F;
    • Schmid, Patrick;
    • Limacher, Andreas;
    • Branca, Mattia;
    • Calmy, Alexandra;
    • Study, the Swiss HIV Cohort
    Publication type:
    Article
    23
    24

    Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.

    Published in:
    Open Forum Infectious Diseases, 2024, v. 11, n. 7, p. 1, doi. 10.1093/ofid/ofae365
    By:
    • Scholten, Stefan;
    • Cahn, Pedro;
    • Portilla, Joaquín;
    • Bisshop, Fiona;
    • Hodder, Sally;
    • Ruane, Peter;
    • Kaplan, Richard;
    • Wynne, Brian R;
    • Man, Choy Y;
    • Grove, Richard;
    • Wang, Ruolan;
    • Jones, Bryn;
    • Ait-Khaled, Mounir;
    • Kisare, Michelle;
    • Okoli, Chinyere
    Publication type:
    Article
    25
    26

    Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study

    Published in:
    Open Forum Infectious Diseases, 2024, v. 11, n. 5, p. 1, doi. 10.1093/ofid/ofae227
    By:
    • Ait-Khaled, Mounir;
    • Oyee, James;
    • Ooi, Adrian Yit Reen;
    • Wynne, Brian;
    • Maldonado, Andres;
    • Jones, Bryn;
    • Wang, Tao
    Publication type:
    Article
    27
    28
    29

    Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study.

    Published in:
    Open Forum Infectious Diseases, 2024, v. 11, n. 4, p. 1, doi. 10.1093/ofid/ofae160
    By:
    • Vasylyev, Marta;
    • Wit, Ferdinand W N M;
    • Jordans, Carlijn C E;
    • Soetekouw, Robin;
    • Lelyveld, Steven F L van;
    • Kootstra, Gert-Jan;
    • Delsing, Corine E;
    • Ammerlaan, Heidi S M;
    • Kasteren, Marjo E E van;
    • Brouwer, Annemarie E;
    • Leyten, Eliane M S;
    • Claassen, Mark A A;
    • Hassing, Robert-Jan;
    • Hollander, Jan G den;
    • van den Berge, Marcel;
    • Roukens, Anna H E;
    • Bierman, Wouter F W;
    • Groeneveld, Paul H P;
    • Lowe, Selwyn H;
    • Welzen, Berend J van
    Publication type:
    Article
    30
    31
    32
    33
    34

    A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes.

    Published in:
    Open Forum Infectious Diseases, 2023, v. 10, n. 11, p. 1, doi. 10.1093/ofid/ofad542
    By:
    • Santos, José R;
    • Domingo, Pere;
    • Portilla, Joaquín;
    • Gutiérrez, Félix;
    • Imaz, Arkaitz;
    • Vilchez, Helem;
    • Curran, Adrià;
    • Valcarce-Pardeiro, Nieves;
    • Payeras, Antoni;
    • Bernal, Enrique;
    • Montero-Alonso, Marta;
    • Yzusqui, Miguel;
    • Clotet, Bonaventura;
    • Videla, Sebastià;
    • Moltó, José;
    • Paredes, Roger
    Publication type:
    Article
    35

    Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis.

    Published in:
    Open Forum Infectious Diseases, 2023, v. 10, n. 11, p. 1, doi. 10.1093/ofid/ofad526
    By:
    • Kabra, Madhusudan;
    • Barber, Tristan J;
    • Allavena, Clotilde;
    • Marcelin, Anne-Geneviève;
    • Giambenedetto, Simona Di;
    • Pasquau, Juan;
    • Gianotti, Nicola;
    • Llibre, Josep M;
    • Rial-Crestelo, David;
    • Miguel-Buckley, Rosa De;
    • Blick, Gary;
    • Turner, Matthew;
    • Harrison, Cale;
    • Wynne, Tammy;
    • Verdier, Gustavo;
    • Parry, Chris M;
    • Jones, Bryn;
    • Okoli, Chinyere;
    • Donovan, Cynthia;
    • Priest, Julie
    Publication type:
    Article
    36

    Strengthening the Evidence: Similar Rates of Neural Tube Defects Among Deliveries Regardless of Maternal HIV Status and Dolutegravir Exposure in Hospital Birth Surveillance in Eswatini.

    Published in:
    Open Forum Infectious Diseases, 2023, v. 10, n. 9, p. 1, doi. 10.1093/ofid/ofad441
    By:
    • Gill, Michelle M;
    • Khumalo, Philisiwe;
    • Chouraya, Caspian;
    • Kunene, Mthokozisi;
    • Dlamini, Futhi;
    • Hoffman, Heather J;
    • Scheuerle, Angela E;
    • Nhlabatsi, Bonisile;
    • Mngometulu, Wiseman;
    • Dlamini-Madlopha, Ntombikayise;
    • Mthunzi, Nompumelelo;
    • Mofenson, Lynne
    Publication type:
    Article
    37
    38
    39

    Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients With HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania.

    Published in:
    Open Forum Infectious Diseases, 2023, v. 10, n. 7, p. 1, doi. 10.1093/ofid/ofad321
    By:
    • Ntamatungiro, Alex J;
    • Eichenberger, Anna;
    • Okuma, James;
    • Vanobberghen, Fiona;
    • Ndege, Robert;
    • Kimera, Namvua;
    • Francis, Joel M;
    • Kagura, Juliana;
    • Weisser, Maja;
    • Group, for the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) Study
    Publication type:
    Article
    40

    Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance.

    Published in:
    Open Forum Infectious Diseases, 2022, v. 9, n. 11, p. 1, doi. 10.1093/ofid/ofac610
    By:
    • Buckley, Rosa De Miguel;
    • Rial-Crestelo, David;
    • Montejano, Rocío;
    • Pinto, Adriana;
    • Jimenez-Gonzalez, María;
    • Lagarde, Maria;
    • Esteban-Cantos, Andrés;
    • Aranguren-Rivas, Paula;
    • Cadiñanos, Julen;
    • Bisbal, Otilia;
    • Castro, Juan Miguel;
    • Santacreu-Guerrero, Mireia;
    • Bermejo-Plaza, Laura;
    • Moreno, Victoria;
    • Hernando, Asunción;
    • Martín-Carbonero, Luz;
    • Rubio, Rafael;
    • Delgado, Rafael;
    • Arribas, José Ramón;
    • Pulido, Federico
    Publication type:
    Article
    41
    42

    Dolutegravir Resistance in Malawi's National HIV Treatment Program.

    Published in:
    Open Forum Infectious Diseases, 2022, v. 9, n. 5, p. 1, doi. 10.1093/ofid/ofac148
    By:
    • Oosterhout, Joep J van;
    • Chipungu, Chifundo;
    • Nkhoma, Lyse;
    • Kanise, Hope;
    • Hosseinipour, Mina C;
    • Sagno, Jean Babtiste;
    • Simon, Katherine;
    • Cox, Carrie;
    • Hoffman, Risa;
    • Steegen, Kim;
    • Matola, Bilaal W;
    • Phiri, Sam;
    • Jahn, Andreas;
    • Nyirenda, Rose;
    • Heller, Tom
    Publication type:
    Article
    43
    44
    45
    46
    47
    48
    49
    50

    Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation.

    Published in:
    Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-30902-7
    By:
    • Deodhar, Suyash;
    • Sillman, Brady;
    • Bade, Aditya N.;
    • Avedissian, Sean N.;
    • Podany, Anthony T.;
    • McMillan, JoEllyn M.;
    • Gautam, Nagsen;
    • Hanson, Brandon;
    • Dyavar Shetty, Bhagya L.;
    • Szlachetka, Adam;
    • Johnston, Morgan;
    • Thurman, Michellie;
    • Munt, Daniel J.;
    • Dash, Alekha K.;
    • Markovic, Milica;
    • Dahan, Arik;
    • Alnouti, Yazen;
    • Yazdi, Alborz;
    • Kevadiya, Bhavesh D.;
    • Byrareddy, Siddappa N.
    Publication type:
    Article